Phaseline

Targets › HEXA

HEXA (Beta-hexosaminidase subunit alpha): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2027.

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides. The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated…. (UniProt, P06865)

Open in Phaseline: the race on HEXA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dr. Anupam SehgalTSHA-101
AAV9 viral vector containing HEXA and HEXB genes
HEXA, HEXBPhase 1Infantile GM2 Gangliosidosis (Disorder)Mar 2027

Conditions

Infantile GM2 Gangliosidosis (Disorder) (1)

Modalities

protein or peptide (1)

Companies

Dr. Anupam Sehgal (1)

Related targets

HEXB (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.